Castle Biosciences CSTL Finite Lived Intangible Assets - Gross
Finite Lived Intangible Assets - Gross at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsGross.
The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Castle Biosciences's finite lived intangible assets - gross.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Castle Biosciences's finite lived intangible assets - gross?
- Castle Biosciences (CSTL) reported finite lived intangible assets - gross of $154.06M in Q1 2026.
- How has Castle Biosciences's finite lived intangible assets - gross changed year-over-year?
- Castle Biosciences's finite lived intangible assets - gross increased by 22.4% year-over-year, from $125.88M to $154.06M.
- What is the long-term trend for Castle Biosciences's finite lived intangible assets - gross?
- Over 4 years (2021 to 2025), Castle Biosciences's finite lived intangible assets - gross has grown at a 14.1% compound annual growth rate (CAGR), from $90.88M to $154.06M.
- What does finite lived intangible assets - gross mean?
- This metric tracks the total historical cost of intangible assets that have a defined useful life, such as patents, software licenses, or customer relationships. It excludes assets with indefinite lives like certain trademarks or goodwill. It is a key indicator of the company's investment in intellectual property and intangible competitive advantages.